Switch theme
Sign up to access all valuation multiples
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
1984
154
LTM Revenue $57.7M
LTM EBITDA $15.9M
$337M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medistim has a last 12-month revenue (LTM) of $57.7M and a last 12-month EBITDA of $15.9M.
In the most recent fiscal year, Medistim achieved revenue of $54.4M and an EBITDA of $15.2M.
Medistim expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medistim valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.7M | XXX | $54.4M | XXX | XXX | XXX |
| Gross Profit | $45.9M | XXX | $43.3M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $15.9M | XXX | $15.2M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $13.6M | XXX | $12.8M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $10.6M | XXX | $10.2M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medistim's stock price is NOK 197 (or $19).
Medistim has current market cap of NOK 3.6B (or $352M), and EV of NOK 3.4B (or $337M).
See Medistim trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $337M | $352M | XXX | XXX | XXX | XXX | $0.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medistim has market cap of $352M and EV of $337M.
Medistim's trades at 6.2x EV/Revenue multiple, and 22.1x EV/EBITDA.
Equity research analysts estimate Medistim's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medistim has a P/E ratio of 33.2x.
See valuation multiples for Medistim and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $352M | XXX | $352M | XXX | XXX | XXX |
| EV (current) | $337M | XXX | $337M | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 21.2x | XXX | 22.1x | XXX | XXX | XXX |
| EV/EBIT | 24.7x | XXX | 26.3x | XXX | XXX | XXX |
| EV/Gross Profit | 7.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 33.2x | XXX | 34.7x | XXX | XXX | XXX |
| EV/FCF | 29.4x | XXX | 29.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedistim's last 12 month revenue growth is 10%
Medistim's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Medistim's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medistim's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medistim and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medistim acquired XXX companies to date.
Last acquisition by Medistim was XXXXXXXX, XXXXX XXXXX XXXXXX . Medistim acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medistim founded? | Medistim was founded in 1984. |
| Where is Medistim headquartered? | Medistim is headquartered in Norway. |
| How many employees does Medistim have? | As of today, Medistim has 154 employees. |
| Who is the CEO of Medistim? | Medistim's CEO is Ms. Kari Eian Krogstad. |
| Is Medistim publicy listed? | Yes, Medistim is a public company listed on OSL. |
| What is the stock symbol of Medistim? | Medistim trades under MEDI ticker. |
| When did Medistim go public? | Medistim went public in 2004. |
| Who are competitors of Medistim? | Similar companies to Medistim include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Medistim? | Medistim's current market cap is $352M |
| What is the current revenue of Medistim? | Medistim's last 12 months revenue is $57.7M. |
| What is the current revenue growth of Medistim? | Medistim revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Medistim? | Current revenue multiple of Medistim is 5.8x. |
| Is Medistim profitable? | Yes, Medistim is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medistim? | Medistim's last 12 months EBITDA is $15.9M. |
| What is Medistim's EBITDA margin? | Medistim's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Medistim? | Current EBITDA multiple of Medistim is 21.2x. |
| What is the current FCF of Medistim? | Medistim's last 12 months FCF is $11.5M. |
| What is Medistim's FCF margin? | Medistim's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Medistim? | Current FCF multiple of Medistim is 29.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
